HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Soldiering Through Scrutiny, Nu Skin Launches Growth Plan For China

This article was originally published in The Rose Sheet

Executive Summary

Nu Skin aims to achieve “higher levels of penetration” in China by expanding its direct-selling platform to additional provinces and tripling the number of stores and sales centers it operates by 2017. Meanwhile, short-seller Citron Research directs FDA and FTC to advertising for Nu Skin’s ageLOC line, which it asserts is rife with “unsubstantiated medical claims.”

You may also be interested in...



In Brief

To consider new data, Europe’s Scientific Committee on Consumer Safety plans to take another look at the safety of parabens in cosmetic products. More news in brief.

FDA Warns Lancome For Gene/Stem-Cell Claims: A Signal To Marketplace?

Claims for L’Oreal’s Lancome brand’s Genifique anti-aging line identify the products as drugs, FDA says. The agency cites claims that the brand’s technology “boosts the activity of genes” and “has been shown to improve the condition” around stem cells – language not unique in the anti-aging cosmeceutical market.

Nu Skin Unfazed By Allegations Of China Violations, Projects More Growth

Following allegations from short seller Citron Research that it operates an illegal “pyramid compensation scheme” in China, Nu Skin gives investors a peek into its business model. The firm recorded sales growth of 40% in its second quarter, driven by a 152% jump in China, and “the best is yet to come,” Nu Skin says.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1133273

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel